Artesunate-amodiaquine versus artesunatesulfadoxine- pyrimethamine for uncomplicated falciparum malaria in children

Main Article Content

Novie H. Rampengan
Jane Metusala
Ronald Chandra
Praevilia Salendu

Abstract

Background Malaria is a major cause of morbidity and mortality
in children, especially in developing countries. Art emisinin
combination therapy (ACT) has higher rates of parasite clearance
and inhibition of anti-malarial drugs resistance than non-ACT.
Hence, we compared the efficacies of artesunate-amodiaquine
(AS-AQ) versus artesunate-sulfadoxine pyrimethamine (AS-SP)
combination therapies in children with uncomplicated falciparum
malaria.
Objective To compare the fever clearance time, parasite clearance
time, and length of hospital stay in uncomplicated falciparum
malaria patients treated with AS-AQ and AS-SP.
Methods We reviewed the medical records of children aged 1- 14
years with uncomplicated falciparum malaria admitted to Prof.
Dr. R. D. Kandou Hospital between January 2002 - June 2010.
Treatment efficacy was evaluated by fever clearance time, parasite
clearan ce time, and length of hospital stay. The differences
of treatment efficacy between the two groups of therapy were
an alyzed by independent T test.
Results We identified 185 children with uncomplicated
falciparum malaria, 104 cases were treated with AS-AQ while
the other 81 received AS-SP. Parasite clearance time was shorter
in AS-AQ group than in AS-SP group at 1.38 (SD 0.69) versus
1.91 (SD 0.93) days, respectively (95%CI of differences 0.3 0 to
0. 76, P<0.05) . The length of hospital stay was shorterin AS-AQ
group than in the AS-SP group, at 5.01 (SD 1.22) versus 6.04
(SD 0.98) days, respectively (95%CI of differences 0. 71 to 1.35,
P < 0.05). However, there was no statistically significant difference
in fever clearance time between the groups.
Conclusion AS-AQ combination therapy reduces parasite
clearance time and length of hospital stay compared to AS-SP
46 • Paediatrlndones, Vol. 54, No. 1, January 2014
combination therapy in children with uncomplicated falciparum
malaria.

Article Details

How to Cite
1.
Rampengan N, Metusala J, Chandra R, Salendu P. Artesunate-amodiaquine versus artesunatesulfadoxine- pyrimethamine for uncomplicated falciparum malaria in children. PI [Internet]. 28Feb.2014 [cited 17Sep.2019];54(1):46-1. Available from: https://paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/204
Section
Articles
Received 2016-08-16
Accepted 2016-08-16
Published 2014-02-28

References

1. Tjitra E. Malaria treatment with artemisinin combination. In: Suwandono A, editor.National Symposia to Control Malaria; 2004 Nov 29-30; Surabaya. p.1-9.
2. Yeka A, Banek K, Bakyaita N, Staedke SG, Kamya MR, Talisuna A, et al. Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda. PLoS Med 2005;2:el90.
3. Allen EN, Little F, Camba T, Cassam Y, Raman J, Boulle A, et al. Efficacy of sulfadoxine-pyrimethamin with or without artesunate for the treatment of uncomplicated Plasmodium f alciparum malaria in Southern Mozambique: a randomized control trial. Malar J. 2009;8:141.
4. Jensen TP, Bukirwa H, Njama-Meya D, Francis D, Kamya MR, Rosenthal PJ, et al. Use of slide positivity rate to estimate changes in malaria incidence in a cohort of Ugandan children. Malar J. 2009;8:213-20.
5. Suh KN, Kain KC, Keystone JS. Malaria. CMAJ. 2004; 170:1693-702.
6. Van den Eede P, Van HN, Van Overmeic C, Vythlingam I, Due TN, Hung le X, et al. Human Plasmodium knowlesi infections in young children in central Vietnam. Malar J. 2009;8:249.
7. Stauffer W, Fischer PR. Diagnosis and treatment of malariain children. Clin Infect Dis. 2003;37:1340-8.
8. Limpakarnjanarat, Kahnchit. Guidelines for case management of malaria in Indonesia. Geneva: World Health Organization; 2011;10-25.
9. Verdrager J, Arwati, Simanjuntak CH, Saroso JS. Chloroquineresistant falciparum malaria in East Kalimantan, Indonesia. J Trop Med Hyg. 1976;79:58-66.
10. Kumar A, Shrivastava AK, Taksande AM, Singh DK, Rai R. Severe P. falciparum malaria in children in a tertiary care centre of Allahabad region oflndia. The Internet J of Pediatr and Neonatol. 2010;12. DOI: 10.5580/llel.
11. Duret B. Guidelines for the treatment of malaria. Switzerland, WHO; 2006. p.7.
12. Rampengan J, Rampengan TH. Uncomplicated malaria falciparum in children who treated with sulfadoxinepyrimetamine. Indones Med. 1998;38:77-80.
13. Vreugdenhil CJ, Scheper FY, Hoogstraatte SR, Smolders M, Gikunda S, Cobelens FG, et al. Comparison of the parasitologic efficacy of amodiaquine and sulfadoxinepyrimethamine in the treatment of Plasmodium falciparum malaria in the Bungoma district of western Kenya. Am J Trop Med Hyg. 2004;71:537-41.
14. GuthmannJP, AmpueroJ, Fortes F, van Overmeir C, Gabolaud V, Tobback S, et al. Antimalarial efficacy of chloroquine, amodiaquine, sulfadoxine-pyrimethamine, and the combinations of amodiaquine + artesunate and sulfadoxine-pyrimethamine + artesunate in Huambo and Bie provinces, central Angola. Trans R Soc Trop Med Hyg. 2005;99:485-92.
15. Hamour S, Melaku Y, Keus K, WambuguJ, Atkin S, Montgomery J, et al. Malaria in the Nuba Mountains of Sudan: bas eline genotypic resistance and efficacy of the artesunate plus sulfadoxine-pyrimethamine and artesunate plus amodiaquine combinations.Trans R Soc Trop Med Hyg. 2005;99:548-54.
16. Tall A, Rabarijaona LP, Robert V, Bedja SA, Ariey F, Randriananriveloj osia M. Efficacy of artesunate plus amodiaquine, artesunate plus sulfadoxine-pyrimethamine, and chloroquine plus sulfadoxine-pyrimethamine in patients with uncomplicated Plasmodium falciparum in the Comoros Union. Acta Trop. 2007;102:176-81.
1 7. Adam I, Magzoub M, Osman ME, Khalil IF, Alifragis M, Elmardi KA. A fixed dose- 24 hour regimen of artesunate plus sulfadoxine-pyrimethamine for the treatment of uncomplicated Plasmodium falciparum malaria in Eastern Sudan. Ann Clin Microbiol Antimicrob. 2006;5:18-22.
18. Ambroise-Thomas P, Binka F, Blolan P, Carroll D, Foster S, Gaye O, Greenwood B, et al. In: Antimalarial drug combination therapy. Report of a WHO technical consultation. WHO, Geneva; 2001.p.5.